Crystalline forms of psilacetin
Crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin), compositions containing that crystalline form, and their methods of use are disclosed. The crystalline forms of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) according to the disclosure include crystalline 4-acetoxy-N,N-dimethyltryptammonium hydrofumarate, the fumarate salt of psilacetin, and/or crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate, and pharmaceutical compositions containing a crystalline form of psilacetin.
1. A method of preventing or treating schizophrenia comprising the step of:
administering to a subject in need thereof a therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate.
2. The method of claim 1 , wherein the crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate is characterized by:
a triclinic, P1 crystal system space group at a temperature of about 200 K;
unit cell dimensions α=8.3965 (13) Å, b=8.9879(14) Å, c=12.0126 (16) Å, α=101.730 (5°), β=100.818 (5°), and γ=112.463 (5°) at a temperature of about 200 K;
an x-ray powder diffraction pattern substantially similar to FIG. 8 ; or
an x-ray powder diffraction pattern characterized by peaks at 7.9, 18.4 and 24.0° 2θ±0.2° 2θ.
3. The method of claim 1 , wherein the method comprises administering the therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate and an excipient.
4. The method of claim 1 , wherein the method comprises administering the therapeutically effective amount of crystalline bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate and a second component selected from (a) a purified psilocybin derivative, (b) one or two purified cannabinoids, and (c) a purified terpene.